News Quartet of biotechs join Nasdaq after stellar IPOs Braveheart Bio, Latigo Biotherapeutics, Attovia Therapeutics, and BlossomHill Therapeutics have finalised their Nasdaq listings, raising over $1.2bn.
News BlossomHill, Vogenx and Latigo reveal IPO plans Three more biotechs have revealed their intentions to list on Nasdaq - BlossomHill, Vogenx, and Latigo - as 2026 heads for a record IPO haul.
News SanegeneBio raises $110m for RNAi, plus other financings Biotech financings this week include SanegeneBio's Lilly-backed $110m Series B, with Sidera, D3 Bio, BlossomHill, and Prolynx also raising new funds.
News Boehringer signs AI drug discovery deal with Owkin Boehringer Ingelheim has joined Sanofi and AstraZeneca in signing up to deploy Owkin's AI platform K Pro in its drug discovery operations.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.